首页 | 本学科首页   官方微博 | 高级检索  
相似文献
 共查询到19条相似文献,搜索用时 828 毫秒
1.
目的 构建Sj-FABPc表达克隆,获得大量纯化rSj-FABPc重组(日本血吸虫脂肪酸结合蛋白)抗原,了解其作为侯选疫苗抗原的潜能。方法 以PCR法从Sj-cDNA库中扩增出目的基因片段后亚克隆入表达载体pGEX-6P-1进行融合表达,经Glutathione Sepharose ^TM 4B亲和层析柱和PreScission^TM Protease酶切后纯化出rSj-FABPc,Western  相似文献   

2.
目的 构建基因工程菌株、获得重组蛋白Sj-FABPc(日本血吸虫脂肪酸结合蛋白)。方法 用PCR法从日本血吸虫cDNA文库中扩增Sj-FABPc基因片段,再将该片段重组于pGEM-T中并进行DNA测序鉴定,经酶切后将目的片段构建成重组质粒pGEX-6P-1/Sj-FABPc,转化于大肠杆菌BL21,IPTG诱导表达。用Glutathione Sepharose^TM 4B亲和层析柱对表达产物进行纯  相似文献   

3.
HBV X蛋白结合共同转录因子ⅡB的研究   总被引:1,自引:1,他引:0  
目的 研究乙型肝炎病毒X蛋白(HBV X蛋白)能否结合共同转录因子ⅡB(TFⅡB)。方法 应用体外蛋白与蛋白结合试验和Far-Western Blot试验,以及细胞内联合免疫沉淀试验。结果 HBV X蛋白能直接与普通TFⅡ B结合。  相似文献   

4.
目的 研究常用抗结核药物与其它抗结核药物联合使用对多耐药结核菌(MDR-MTB)的抗菌效力。方法 按照部分耐药浓度(FIC)方法测定(MDR-MTB)单独用药及联合用药时标准结核分枝杆菌的最低抑菌浓度(MIC),临床分离株的最低抑菌浓度(MICs),按照FIC公式,计算其是否有协同作用。结果 INH、RFP、EMB、CAM和INH、RFP、PZA、OFLX组合对13株临床分离的MDR-MTB的FI  相似文献   

5.
慢性重型肝炎患者血小板变化及其机制   总被引:6,自引:0,他引:6  
采用Born法、ELISA法、放射免疫分析法和电镜对38例慢性重型肝炎(慢重肝)患者血小板功能、调节介质和超微结构进行了系列研究。结果发现:血浆β-血小板球蛋白(β-TG)显著升高,血小板聚集率(PAR)、血小板TXB2及cAMP含量明显降低;PAR与血小板TXB2及cAMP、TXB2与cAMP之间均呈非常显著相关,血浆β-TG与PAR及cAMP之间呈非常显著负相关;超微结构以血小板活化和退行性变为突出改变。分析认为慢重肝患者可能因体内各种因素作用,使血小板发生持续性激活,引起获得性血小板贮存池病。  相似文献   

6.
目的:评价转染AT1我核菩酸(AT1A)对血管平滑肌细胞(VSMCs)血管紧张Ⅱ(AngⅡ)受体亚型mRNA表达、蛋白激酶C(PKC)、丝裂素活化蛋白激酶P^38(P^38MAPK)蛋白表达,及蛋白核酸合成的作用。方法:RT-PCR克隆AT1 cDNA序列(476bp),将克隆的AT1 cDNA反向插入PcDNA3.1,构建一完整的含AT1A的质粒(PAT1A),测序鉴定。转染培养的大鼠VSMCs  相似文献   

7.
目的 了解重组的日本血吸虫中国大陆株脂肪酸结合蛋白(rSj-FABPc)的特性及预测其抗原表位。方法 以PCR方法从Sj-cDNA文库中扩增Sj-FABPc基因片段,并亚克隆于载体pGEM-T,对其核苷酸序列进行测定。以GOLDKEY软件和Swiss-Model数据库分析Sj-FABPc的核苷酸序列和其编码的蛋白质特性,预测重组抗原的表位。结果 核酸序列分析证明,克隆基因确为Sj-FABPc,并由  相似文献   

8.
应用TNF-α和IFN-α依赖细胞MTT比色分析法,研究了5例自体骨髓移植(ABMT)病人血清中TNF-α、IFN-α活性,。处于完全缓解期的急性粒细胞性白血病(AML)血清中TNF-α生显著的高于正常成人(PBs)组(P〈0.05);IFN-α活性明显低于PBs组(P〈0.01)。ABMT前血清中的TNF-α、IFN-α活性显著高于ABMT后9-10天(P〈0.05)和21天(P〈0.05);与  相似文献   

9.
测定32例糖尿病阳萎者11例无阳萎者血小板最大聚集率(MAR),血栓素B2(TXB2)和6-酮-前列腺素F1α(6-keto-PGF1α),并与正常人对照,结果表明,糖尿病有无阳萎组MAR,TXB2及TXB2/6-keto-PGF1α比值均高于正常组(P〈0.05~0.01),而6-keto-PGF1α水平低下(P〈0.01),糖尿病阳萎组这些指标变化更为明显,与无阳萎组比较,阳萎组MAR及TXB  相似文献   

10.
NATIONALPROGRAMOFMALARIACONTROLOFPEOPLE’SREPUBLICOFCHINAXuShu—HuiDepartmentofparasiticDiseases,MinistryofPublicHealthofChina(...  相似文献   

11.
目的 探讨HBV X蛋白与细胞色素c氧化酶Ⅲ(COXⅢ)之间的结合作用.方法 采用交合实验验证HBV X蛋白和COXⅢ在酵母细胞内的结合作用,利用离体结合实验证实两者在体外的结合作用,采用免疫共沉淀实验证实两者在哺乳动物细胞中的结合作用.结果 携带COXⅢ基因的酵母与携带X基因的酵母交合后发生反应,β-半乳糖苷酶(LacZ)活性检测菌落呈现蓝色,离体结合实验Western印迹中出现特异性结合活性反应条带,提示X蛋白和COXⅢ在体外存在直接相互作用,免疫共沉淀实验在相对分子质量为17 000处出现蛋白条带,提示在哺乳动物细胞水平仍能检测到X蛋白和COXⅢ的特异结合.结论 COXⅢ与X蛋白在原核细胞和哺乳动物细胞中均存在特异性结合,HBV可能通过此反应干扰线粒体呼吸链功能及能量代谢过程.  相似文献   

12.
Hepatitis delta virus(HDV) seems to strongly suppress hepatitis B virus(HBV)replication, although little is known about the mechanism of this interaction. Both these viruses show a dynamic distribution of mutants, resulting in viral quasispecies. Next-generation sequencing is a viable approach for analyzing the composition of these mutant spectra. As the regulatory hepatitis B X protein(HBx) is essential for HBV replication, determination of HBV X gene(HBX)quasispecies complexity in HBV/HDV infection compared to HBV monoinfection may provide information on the interactions between these two viruses.AIM To compare HBV quasispecies complexity in the HBX 5' region between chronic hepatitis delta(CHD) and chronic HBV mono-infected patients.METHODS Twenty-four untreated patients were included: 7/24(29.2%) with HBeAgnegative chronic HBV infection(CI, previously termed inactive carriers), 8/24(33.3%) with HBeAg-negative chronic hepatitis B(CHB) and 9/24(37.5%) with CHD. A serum sample from each patient was first tested for HBV DNA levels.The HBX 5' region [nucleotides(nt) 1255-1611] was then PCR-amplified for subsequent next-generation sequencing(MiSeq, Illumina, United States). HBV quasispecies complexity in the region analyzed was evaluated using incidencebased indices(number of haplotypes and number of mutations), abundancebased indices(Hill numbers of order 1 and 2), and functional indices(mutation frequency and nucleotide diversity). We also evaluated the pattern of nucleotide changes to investigate which of them could be the cause of the quasispecies complexity.RESULTS CHB patients showed higher median HBV-DNA levels [5.4 logIU/mL,interquartile range(IQR) 3.5-7.9] than CHD(3.4 logIU/mL, IQR 3-7.6)(P = n.s.)or CI(3.2 logIU/mL, IQR 2.3-3.5)(P < 0.01) patients. The incidence and abundance indices indicated that HBV quasispecies complexity was significantly greater in CI than CHB. A similar trend was observed in CHD patients, although only Hill numbers of order 2 showed statistically significant differences(CHB2.81, IQR 1.11-4.57 vs CHD 8.87, 6.56-11.18, P = 0.038). There were no significant differences in the functional indices, but CI and CHD patients also showed a trend towards greater complexity than CHB. No differences were found for any HBV quasispecies complexity indices between CHD and CI patients. G-to-A and C-to-T nucleotide changes, characteristic of APOBEC3 G, were higher in CHD and CI than in CHB in genotype A haplotypes, but not in genotype D. The proportion of nt G-to-A vs A-to-G changes and C-to-T vs T-to-C changes in genotype A and D haplotypes in CHD patients showed no significant differences. In CHB and CI the results of these comparisons were dependent on HBV genotype.CONCLUSION The lower-replication CHD and CI groups show a trend to higher quasispecies complexity than the higher-replication CHB group. The mechanisms associated with this greater complexity require elucidation.  相似文献   

13.
目的 构建含甲胎蛋白(AFP)启动子和增强子的反义乙型肝炎病毒X基因(HBX)真核表达载体,研究其特异性和有效性,为开发肝癌细胞特异性HBX反义RNA基因治疗乙型肝炎病毒(HBV)奠定基础。方法 聚合酶链反应(PCR)扩增HBX(1370—1872nt)基因,克隆至EB病毒表达载体,双轮PCR筛选、鉴定基因插入方向。脂质体转染肝癌细胞和ECV304细胞,Northernblot检测HBX mRNA的表达,酶联免疫试验(ELISA)检测HBV抗原,荧光定量PCR检测HBV DNA。结果 成功构建正、反义RNA表达载体pEBAF—s—HBX、pEBAF—as—HBX。Northernblot证实反义RNA仅在AFP阳性的肝癌细胞中表达。pEBAF—as—HBX转染3d后,可显著抑制2.2.15细胞HBV复制和抗原表达,其HBsAg、HBeAg抗原表达较正义对照分别下降37.9%和36.8%,HBV DNA降低25%。结论 反义RNA表达载体pEBAF—as—HBX仅在肝癌细胞中特异表达、并可有效抑制HBV,有良好的开发应用前景。  相似文献   

14.
目的构建靶向乙型肝炎病毒X基因(HBX)的shRNA表达载体pSilencer3.1-shHBX,观察其体外抑制HBX在HepG2细胞中表达的作用,为应用RNA干扰技术进一步研究HBX基因的功能奠定基础。方法设计并构建靶向HBx的shRNA表达载体pSilencer3.1-shHBX,脂质体转染法将HBX表达载体pcDNA3.1-HBx与pSilencer3.1-shHBX共转染人肝癌HepG2细胞,培养72h后以RT-PCR检测HBX基因表达情况,以Western blot检测HBX蛋白的表达量。结果经酶切和测序鉴定,构建的重组质粒pSilencer3.1-shHBX与设计一致。该质粒使HBX基因mRNA表达量降低47.1%,使HBx蛋白表达量降低58.9%,而阴性对照质粒无此作用。结论成功构建靶向HBXshRNA表达载体pSilencer3.1-shHBX,该质粒可体外抑制HBX在HepG2细胞中的表达。  相似文献   

15.
16.
17.
Hepatitis B virus x protein (HBX), a product of hepatitis B virus (HBV), is a multifunctional protein that regulates viral replication and various cellular functions. Recently, HBX has been shown to induce autophagy; however, the responsible mechanism is not fully known. In this study, we established stable HBX‐expressing epithelial Chang cells as the platform to study how HBX induced autophagy. The results showed that the overexpression of HBX resulted in starvation‐induced autophagy. HBX‐induced autophagy was related to its ability to dephosphorylate/activate death‐associated protein kinase (DAPK). The block of DAPK by its siRNA significantly counteracted HBX‐mediated autophagy, confirming the positive role of DAPK in this process. HBX also induced Beclin 1, which functions at the downstream of the DAPK‐mediated autophagy pathway. Although HBX could activate JNK, a kinase known to participate in autophagy in certain conditions, the change in JNK failed to influence HBX‐induced autophagy. In conclusion, HBX induces autophagy via activating DAPK in a pathway related to Beclin 1, but not JNK. This new finding should help us to understand the role of autophagy in HBX‐mediated pathogenesis and thus may provide targets for intervening HBX‐related disorders.  相似文献   

18.
19.
La蛋白与乙型肝炎病毒mRNA稳定性和蛋白质表达的相关性   总被引:1,自引:0,他引:1  
目的研究La蛋白与乙型肝炎病毒(HBV)mRNA稳定性和蛋白质表达之间的相关性。方法设计并合成La蛋白mRNA特异性小干扰RNA(siRNA),转染HepG2.2.15细胞,继续培养3d后分别裂解转染和未转染siRNA的细胞l抽提蛋白质,Westernblot检测La蛋白含量变化;于转染后的第1、2、3、5、7、9天分别收集细胞培养上清液,实时荧光定量聚合酶链反应技术检测上清液中HBVDNA的变化情况,电化学发光分析技术检测乙型肝炎表面抗原,乙型肝炎e抗原含量变化情况。结果La蛋白在转染siRNA的HepG2.2.15细胞中表达明显低于未转染siRNA的细胞;转染siRNA的细胞分泌到上清液中乙型肝炎表面抗原、乙型肝炎e抗原和HBVDNA的含量也明显低于未转染siRNA的细胞。结论在HepG2.2.15细胞内,La蛋白与HBVmRNA稳定性和蛋白质表达具有功能相关性。  相似文献   

设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号